1. From the Program on Regulation, Therapeutics, and Law, Division of Pharmacoepidemiology and Pharmacoeconomics (W.B.F., B.N.R., J.A., A.S.K.) and the Division of Pulmonary and Critical Care Medicine (W.B.F.), Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School (W.B.F., B.N.R., J.A., A.S.K.) — both in Boston.